Skip to content Skip to footer
Subscribe Now
Valo & Merk KGaA
NEWS

Valo Health Inks Over $3B Partnership with Merck KGaA to Advance Novel Therapies for Neurodegenerative Disorders

Shots:  Valo Health has entered into a strategic collaboration with Merck KGaA to accelerate therapeutic discovery for Parkinson’s disease & related neurodegenerative disorders As per the deal, Valo Health will receive an upfront & milestone payment totaling over $3B, with royalties & R&D funding Collaboration will use Valo’s AI-enabled human causal biology platform to discover &…
November 21, 2025

Read more

NEWS

Arrowhead Enters a ~$2.2B Deal with Novartis for ARO-SNCA and TRiM-Based Therapies to Treat Neurodegenerative Diseases

Shots: Arrowhead has granted Novartis exclusive global rights to develop, manufacture, & commercialize ARO-SNCA, which leverages the TRiM platform for SC dosing & targeted gene delivery to treat synucleinopathies, incl. Parkinson’s disease As per the deal, Arrowhead will receive $200M upfront & ~$2B in development, regulatory, and sales milestones, with tiered royalties on sales up…
September 3, 2025

Read more

VIEWPOINTS_Craig Thompson_2023
VIEWPOINTS

Craig Thompson, CEO of Cerevance Shares Insights from the Preclinical Data Presented at the Society for Neuroscience (SFN) 2022

Shots:   Craig shared with our readers the preclinical study results of C101248 demonstrating its pharmacological activity and validation of the NETSseq platform as an effective method to interpret new therapeutic targets for Alzheimer’s disease  He also elaborated on how the combination of the NETSseq platform and C101248 will help in the identification and development of…
March 20, 2023

Read more

Viewpoints_Karl Bradshaw
VIEWPOINTS

Karl Bradshaw, VP of Corporate Development at Metabolon, Shares Insights on the Partnership with The University of Oxford Parkinson’s Disease Centre

Shots: Karl spoke on Metabolon’s partnership with the University of Oxford Parkinson’s Disease Centre (OPDC) to identify new metabolomic biomarkers for the advancement of Parkinson’s research  Karl also talked about the metabolomic changes which occur in Parkinson’s disease and how Metabolon will support OPDC's mission to improve research and understanding of the biology of early…
September 21, 2022

Read more

PharmaShots Interview In Conversation with Four Prominent Leaders from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference
VIEWPOINTS

PharmaShots Interview: In Conversation with Four Prominent Leaders* from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference

Shots: The interview provided an understanding of the data from its Alzheimer’s disease pipeline at the AD/PD Conference The spokespeople also talked about the clinical trial data and key mechanisms of Eisai’s anti-amyloid compound in AD  The discussion showed gave a gist of four key symposium presentations that showed how its lead candidate has the…
June 27, 2022

Read more